{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ren Y"],"funding":["Natural Science Foundation of Hebei Province","This work was supported by the Key Project of Natural Science Foundation of Hebei Province","National Natural Science Foundation of China"],"pagination":["16982"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8379215"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["HBV infection is recognized as a serious global health problem, and hepatitis B virus infection is a complicated chronic disease leading to liver cirrhosis (LC) and hepatocellular carcinoma (HCC). New biochemical serum markers could be used to advance the diagnosis and prognosis of HBV-associated liver diseases during the progression of chronic hepatitis B into cirrhosis and HCC. We determined whether the 4210 Da and 1866 Da polypeptides are serum metabolite biomarkers of hepatopathy with hepatitis B virus. A total of 570 subjects were divided into five groups: healthy controls, those with natural clearance, and patients with CHB, LC, and HCC. The 1866 Da and 4210 Da polypeptides were measured by Clin-ToF II MALDI-TOF-MS. There were significant differences in 4210 Da and 1866 Da levels amo"],"journal":["Scientific reports"],"pubmed_title":["4210 Da and 1866 Da polypeptides as potential biomarkers of liver disease progression in hepatitis B virus patients."],"pmcid":["PMC8379215"],"funding_grant_id":["81402729","H2016206411","H2016206576"],"pubmed_authors":["Gao P","Yang L","Li T","Ma N","Ren Y","Gao X","Liu D","Wang J","Yan H","Li M","Liu W","Wang L"],"additional_accession":[]},"is_claimable":false,"name":"4210 Da and 1866 Da polypeptides as potential biomarkers of liver disease progression in hepatitis B virus patients.","description":"HBV infection is recognized as a serious global health problem, and hepatitis B virus infection is a complicated chronic disease leading to liver cirrhosis (LC) and hepatocellular carcinoma (HCC). New biochemical serum markers could be used to advance the diagnosis and prognosis of HBV-associated liver diseases during the progression of chronic hepatitis B into cirrhosis and HCC. We determined whether the 4210 Da and 1866 Da polypeptides are serum metabolite biomarkers of hepatopathy with hepatitis B virus. A total of 570 subjects were divided into five groups: healthy controls, those with natural clearance, and patients with CHB, LC, and HCC. The 1866 Da and 4210 Da polypeptides were measured by Clin-ToF II MALDI-TOF-MS. There were significant differences in 4210 Da and 1866 Da levels amo","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2025-04-04T12:28:39.18Z","creation":"2022-02-11T09:48:52.193Z"},"accession":"S-EPMC8379215","cross_references":{"pubmed":["34417517"],"doi":["10.1038/s41598-021-96581-4"]}}